Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
[HTML][HTML] Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review
JW Hommes, RJ Verheijden, KPM Suijkerbuijk… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of patients
with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA …
with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA …
[HTML][HTML] Hypertension in thyroid disorders
Arterial hypertension represents a major global health concern; more than one fourth of the
population is affected by high blood pressure. Albeit the underlying cause of the disease …
population is affected by high blood pressure. Albeit the underlying cause of the disease …
[HTML][HTML] Holistic approach to immune checkpoint inhibitor-related adverse events
R Poto, T Troiani, G Criscuolo, G Marone… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …
[HTML][HTML] Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside
Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at
the price of a new array of immune related adverse events. Among these is β-cell failure …
the price of a new array of immune related adverse events. Among these is β-cell failure …
Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer
Background: Inhibitory antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the …
programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the …
[HTML][HTML] Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented
treatment benefits being obtained for cancer patients, including improved patient survival …
treatment benefits being obtained for cancer patients, including improved patient survival …
[HTML][HTML] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
H Matsuoka, T Hayashi, K Takigami, K Imaizumi… - Bmc Cancer, 2020 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death
protein 1 (PD-1) are used for the treatment of various cancer types. However, immune …
protein 1 (PD-1) are used for the treatment of various cancer types. However, immune …
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
RS Goodman, S Jung, JM Balko… - Immunological …, 2023 - Wiley Online Library
Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …
[HTML][HTML] Adverse effects of anti-PD-1/PD-L1 therapy in non-small cell lung cancer
C Su, H Wang, Y Liu, Q Guo, L Zhang, J Li… - Frontiers in …, 2020 - frontiersin.org
Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal
antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging …
antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging …